• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Oral Drug Delivery Market - Controlled and Sustained Release to be Major Revenue Generators - Product Image

Oral Drug Delivery Market - Controlled and Sustained Release to be Major Revenue Generators

  • ID: 1408910
  • November 2010
  • 85 Pages
  • GBI Research

FEATURED COMPANIES

  • ActogeniX NV
  • Bone Medical Limited
  • Chiasma(Israel) Ltd
  • Chimerix Inc
  • Egalet
  • Eurand N.V
  • MORE

“Oral Drug Delivery Market - Controlled and Sustained Release to be Major Revenue Generators”, provides the key data and analyzes the major challenges and drivers for the Oral Drug Delivery Market. The report also provides in-depth analysis of unmet needs, drivers and barriers that impact the global Oral Drug Delivery Market.

Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets. The report is based on proprietary databases, primary and secondary research and in-house analysis by a team of industry experts to provide a comprehensive view of the Oral Drug Delivery Market.

Scope

The scope of this report includes:
- Opportunities and challenges for Oral Drug Delivery Market in the pharmaceuticals industry
- Market revenues and forecasts for Oral Drug Delivery Market in the global pharmaceutical industry from 2009 to 2016.
- The key geographies including the US, Europe, Japan and Emerging Hotspots such as India, Singapore and China.
- Technology trends in Oral Drug Delivery Market. that shape the industry
- Qualitative READ MORE >

FEATURED COMPANIES

  • ActogeniX NV
  • Bone Medical Limited
  • Chiasma(Israel) Ltd
  • Chimerix Inc
  • Egalet
  • Eurand N.V
  • MORE

1.1 List of Tables
1.2 List of Figures

2 Oral Drug Delivery Market – Introduction
2.1 Research Report Guidance

3 Oral Drug Delivery Market Overview
3.1 Global Drug Delivery Market
3.2 Drug Delivery as an Essential Component of the Pharmaceutical/Biotechnology Industry
3.2.1 Role of Drug Delivery in the Pharmaceutical Market
3.3 Patent Expirations and Their Effect on the Pharmaceutical Industry
3.3.1 Risk of Lost Sales for Major Pharmaceutical Companies Due to Patent Expiries
3.4 Repositioning of Existing Drugs through Reformulations - A Major Lifecycle Management Strategy
3.4.1 Repositioning of Marketed or Failed Drugs
3.4.2 Repositioning Through Reformulation

4 Market Overview - Introduction To The Oral Drug Delivery Market
4.1 Comparative Analysis of Oral Drug Delivery with Other Drug Delivery Forms
4.2 Oral Drug Delivery Enhanced/Enabled Products - Overview
4.2.1 Oral Drug Delivery Product Development Parameters
4.2.2 Market Exclusivity for Oral Drug Delivery Enhanced/Enabled Products
4.2.3 Major Therapeutic Areas for Oral Drug Delivery Enabled/Enhanced Products

5 Technology Landscape - Reformulating Injectable Drugs For Oral Delivery
5.1 Technologies Used in Oral Delivery of Peptides and Proteins
5.1.1 Oral Delivery Strategies of Peptides and Proteins - Chemical Modifications of Peptides and Protein Drugs
5.1.2 Oral Delivery Strategies of Peptides and Proteins - Enzyme Inhibitors
5.1.3 Oral Delivery Strategies of Peptides and Proteins - Absorption Enhancements
5.1.4 Oral Delivery Strategies of Peptides and Proteins - Using Mucoadhesive Polymers
5.1.5 Diabetes and Metabolic Disorders
5.1.6 Cardiovascular-related Disorders
5.1.7 Osteoporosis/Osteoarthritis and Bone Related Disorders
5.1.8 Central Nervous System Related Disorders
5.1.9 Oncology
5.2 Innovations Related to Oral Vaccine Development
5.2.1 Oral Vaccine Research Based Study - Live Bacterial Vectors
5.2.2 Oral Vaccine Research Based Study – Use of Particulate Formulations
5.2.3 Oral Vaccine Research Based Study – Use of Non-Toxic Mucosal Adjuvants
5.2.4 Oral Vaccine Research Based Study-Transgenic Plants

6 Technology Landscape - Nanotechnology in Drug Delivery
6.1 Introduction
6.2 Application of Nanotechnology
6.2.1 NanoDRY and NanoCOAT Technology
6.2.2 Polymeric Nano-Delivery System (PNDS)
6.2.3 FluidCrystal NP Oral Nanoparticles
6.2.4 NanoCrystal Technology

7 Technology Landscape - Advances in Oral Prodrug Delivery
7.1 Targeted Prodrug Design
7.1.1 Prodrug Design Targeting Enzymes
7.1.2 Prodrug Design Targeting the Membrane Transporters
7.2 Featured Prodrugs- Anti-Viral
7.2.1 Oseltamivir
7.2.2 Valganciclovir
7.2.3 Famciclovir
7.2.4 Cidofovir
7.2.5 Zanamivir
7.3 Respiratory Prodrugs
7.3.1 Bambuterol
7.4 Featured Prodrugs - Anti-Cancer
7.4.1 Gemcitabine
7.5 Featured Prodrugs - Central Nervous System
7.5.1 Levodopa
7.5.2 LY2140023
7.6 Featured Prodrugs- Antibiotics
7.6.1 Torezolid Phosphate

8 Technology Landscape - Advances in Delayed and Controlled Release Delivery
8.1 Controlled Release Oral Drugs
8.1.1 Dissolution Controlled Release
8.1.2 Diffusion Controlled Release
8.1.3 Diffusion and Dissolution Controlled Systems
8.1.4 Ion-exchange Resins
8.1.5 pH - Independent Formulations
8.1.6 Osmotically Controlled Release
8.1.7 Altered Density Formulations
8.1.8 Types of Tablets Formulations Possible for Controlled Release Oral Drugs
8.1.9 Challenges and Advantages for Controlled Release Oral Drug Delivery Systems
8.1.10 Key Future Applications of Controlled Release Platforms for Oral Therapeutics
8.1.11 Orally Disintegrating Tablets
8.1.12 Minitablets as a Flexible Drug Delivery System
8.1.13 Taste Masking Technologies for Bitter Tasting Oral Drugs

9 Therapeutic Landscape – Oral Drug Delivery Systems Across Major Therapeutic Areas
9.1 Musculoskeletal Disorders
9.1.1 Analysis of Global Osteoporosis Therapeutics Market and Application of Oral Drug Delivery Systems
9.1.2 Analysis of the Global Osteoarthritis Therapeutics Market and Applications of Oral Drug Delivery Systems
9.2 Metabolic Disorders
9.2.1 Analysis of the Global Type 2 Diabetes Therapeutics Market and Application of Oral Drug Delivery Systems
9.2.2 Analysis of the Global Type 1 Diabetes Therapeutics Market and Application of Oral Drug Delivery Systems
9.2.3 Analysis of the Global Anti-Obesity Therapeutics Market and Applications of Oral Drug Delivery Systems
9.3 Oncology
9.3.1 Analysis of the Global Ovarian Cancer Therapeutics Market and Applications of Oral Drug Delivery Systems
9.4 Gastrointestinal Disorders
9.4.1 Analysis of the Global Ulcerative Colitis Therapeutics Market and Applications of Oral Drug Delivery Systems
9.5 Central Nervous System
9.5.1 Analysis of the Global Migraine Therapeutics Market and Applications of Oral Drug Delivery Systems
9.5.2 Analysis of the Global Parkinson’s Disease Therapeutics Market and Applications of Oral Drug Delivery Systems
9.6 Infectious Diseases
9.6.1 Analysis of the Global Pneumonia Therapeutics Market and Applications of Oral Drug Delivery Systems
9.7 Cardiovascular Diseases
9.7.1 Analysis of the Global Hypertension Therapeutics Market and Applications of Oral Drug Delivery Systems

10 Innovative Oral Drug Delivery Companies – Profiles
10.1 Chiasma(Israel) Ltd
10.1.1 Company Overview
10.1.2 Service Portfolio and offerings
10.1.3 Product Pipeline
10.1.4 Recent Updates Related to Licensing Deals, Strategic Consolidations
10.2 Emisphere Technologies Inc
10.2.1 Company Overview
10.2.2 Service Portfolio and offerings
10.2.3 Product Pipeline
10.2.4 Recent Updates Related to Licensing Deals, Strategic Consolidations
10.3 Merrion Pharmaceuticals Plc
10.3.1 Company Overview
10.3.2 Service Portfolio and Offerings
10.3.3 Product Pipeline
10.3.4 Recent Updates Related to Licensing Deals and Strategic Consolidations
10.4 Oramed Pharmaceuticals
10.4.1 Company Overview
10.4.2 Service Portfolio and Offerings
10.4.3 Product Pipeline
10.4.4 Recent Updates Related to Licensing Deals and Strategic Consolidations
10.5 Samyang Corporation
10.5.1 Company Overview
10.5.2 Service Portfolio and offerings
10.5.3 Product Pipeline
10.5.4 Recent Updates Related to Licensing Deals and Strategic Consolidations
10.6 Unigene Laboratories Inc
10.6.1 Company Overview
10.6.2 Service Portfolio and Offerings
10.6.3 Pipeline Products
10.6.4 Recent Updates Related Licensing Deals and Strategic Consolidations
10.7 Bone Medical Limited
10.7.1 Company Overview
10.7.2 Service Portfolio and offerings
10.7.3 Product Pipeline
10.7.4 Recent Updates Related to Licensing Deals and Strategic Consolidations
10.8 Chimerix Inc
10.8.1 Company Overview
10.8.2 Service Portfolio and Offerings
10.8.3 Pipeline Products
10.8.4 Recent Updates Related To Licensing Deals and Strategic Consolidations
10.9 Mucosis B.V
10.9.1 Company Overview
10.9.2 Service Portfolio and Offerings
10.9.3 Product Pipeline
10.9.4 Recent Updates Related to Licensing Deals and Strategic Consolidations
10.10 Immupharma Plc
10.10.1 Company Profile
10.10.2 Service Portfolio and offerings
10.10.3 Product Pipeline
10.10.4 Recent updates related to licensing deals and strategic consolidations
10.11 Access Pharmaceuticals Inc
10.11.1 Company Overview
10.11.2 Service Portfolio and offerings
10.11.3 Product Pipeline
10.11.4 Recent updates related to licensing deals and strategic consolidations
10.12 ActogeniX NV
10.12.1 Company Overview
10.12.2 Service Portfolio and offerings
10.12.3 Product Pipelines
10.12.4 Recent Updates Related to Licensing Deals and Strategic Consolidations
10.13 Egalet
10.13.1 Company Overview
10.13.2 Service Portfolio and offerings
10.13.3 Product Pipeline
10.13.4 Recent Updates Related to Licensing Deals and Strategic Consolidations
10.14 Eurand N.V
10.14.1 Company Overview
10.14.2 Service Portfolio and Offerings
10.14.3 Product Pipeline
10.14.4 Recent Updates Related to Licensing Deals and Strategic Consolidations
10.15 Supernus Pharmaceuticals,Inc
10.15.1 Company Overview
10.15.2 Service Portfolio and offerings
10.15.3 Product Pipeline
10.15.4 Recent updates related to licensing deals and strategic consolidations

11 Strategic Consolidations: Licensing, Partnerships , Mergers and Acquisitions (M&As)
11.1 Licensing and Partnership Deals In the Oral Drug Delivery Sector
11.2 Investments, Funding, Mergers and Acquisition Deals in the Oral Drug Delivery Sector

12 Oral Drug Delivery Market – Appendix
12.1 Market Definitions
12.2 Abbreviations
12.3 Research Methodology
12.3.1 Coverage
12.3.2 Secondary Research
12.3.3 Primary Research
12.3.4 Expert Panel Validation
12.4 Contact Us
12.5 Disclaimer
12.6 Sources

1.1 List of Tables
Table 1: Oral Drug Delivery Market Forecast (2009-2016)
Table 2: Emisphere Technologies- Product Pipeline
Table 3: Merrion Pharmaceuticals – Product Pipeline
Table 4: Oramed Pharmaceuticals – Product Pipeline
Table 5: Samyang Corporation- Product Pipeline
Table 6: Unigene Laboratories Inc - Pipeline Products
Table 7: Bone Medical Limited
Table 8: Access Pharmaceutical – Product Pipeline
Table 9: ActogeniX NV – Product Pipeline
Table 10: Egalet – Product Pipeline
Table 11: Eurand N.V - Product Pipeline
Table 12: Supernus Pharmaceuticals – Product Pipeline

1.2 List of Figures
Figure 1: Global Pharmaceutical Market,by Drug Delivery Methods
Figure 2: Role of Drug Delivery in the Pharmaceutical Market
Figure 3: Drug Delivery as a Key Lifecycle Management Strategy
Figure 4: Pharmaceutical Market, Global , Patent Loss Value ($bn), by Therapy Area (2010-2012)
Figure 5: Total Risk of Lost Sales by Major Pharmaceutical Companies due to Patent Expirations
Figure 6: Reformulation as a Key Technique for Patent Life Extension
Figure 7: Key Drivers for Drug Repositioning
Figure 8: Reformulations vs NCE Approvals,(2002-2009)
Figure 9:Comparative Study of Oral Drug Delivery Market, by Mode of Administration 2009
Figure 10: Oral Drug Delivery Market Forecast (2009-2016)
Figure 11: Major Therapeutic Areas For Oral Drug Delivery Systems, By Number of Marketed Drugs,2009
Figure 12: Oral Insulin, Pipeline Analysis, by Phase And Indication,(2009-2016)
Figure 13: Oral ARB’s - Pipeline Analysis by Pipeline And Phase,(2009-2016)
Figure 14: Oral Calcitonin, Pipeline Analysis, by Pipeline And Phase,(2009-2016)
Figure 15: Oral Bisphosphonates, Pipeline Analysis, by Pipeline And Phase,(2009-2016)
Figure 16: Enzyme Inhibitors, Pipeline Analysis, by Pipeline and Phase,(2009-2016)
Figure 17: Comparative Analysis of Sustained Release and Other Drug Delivery Methods,(2007-2015)
Figure 18: Different Taste Masking Technologies
Figure 19: Pharmaceutical Market, Global, Oral Drug Delivery Enabled Products, by Major Companies
Figure 20: Oral Drug Delivery Enabled Products, Pipeline Analysis, by Therapy Area
Figure 21: Pipeline and Growth Analysis of Various Therapeutic Areas, (2009-2016)
Figure 22: Global Osteoporosis Therapeutics Market Forecast 2009-2016
Figure 23: Global Type 2 Diabetes Therapeutics Market Forecast 2009-2016
Figure 24: Global Type 1 Diabetes Therapeutics Market Forecast 2009-2016
Figure 25: Global Anti-Obesity Therapeutics Market Forecast 2009-2016
Figure 26: Global Ovarian Cancer Therapeutics Market Forecast 2009-2016
Figure 27: Global Ulcerative Colitis Therapeutics Market Forecast 2009-2016
Figure 28: Global Migraine Therapeutics Market Forecast 2009-2016
Figure 29: Global Parkinson’s Disease Therapeutics Market Forecast 2009-2016
Figure 30: Global Pneumonia Therapeutics Market Forecast 2009-2016
Figure 31: Global Hypertension Therapeutics Market Forecast 2009-2016
Figure 32: Licensing and Partnership Deals in the Oral Drug Delivery Sector (2006-2010)
Figure 33: Investments, Funding and M&A Deals in the Oral Drug Delivery Sector (2006-2010)

FEATURED COMPANIES

  • ActogeniX NV
  • Bone Medical Limited
  • Chiasma(Israel) Ltd
  • Chimerix Inc
  • Egalet
  • Eurand N.V
  • MORE

“Oral Drug Delivery Market - Controlled and Sustained Release to be Major Revenue Generators”, provides in-depth analysis of the unmet needs, drivers and barriers that impact the global oral drug delivery market. The report analyzes the markets for oral drug delivery systems in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for these key geographies, as well as for the market’s leading therapeutic segments. The report provides competitive benchmarking for the leading companies in the market and analyzes the mergers, acquisitions and licensing agreements that shape the global oral drug delivery market.

Pharmaceutical Companies Looking at Innovative Drug Delivery Systems to Enhance Their Products - CNS, Gastrointestinal and Hormone and Related Agents are the Focused Therapeutic Areas Using Drug Delivery Systems

Over the last few years, the pharmaceutical industry has seen patent expiries for major blockbuster drugs which have resulted in losses worth billions. More blockbuster drugs are about to lose patent in the coming years. In such a situation, pharmaceutical companies are increasingly adopting various drug delivery systems to enhance their product efficacy, patient compliance and extend patent lives through innovative repositioning and reformulations of existing drugs. This has resulted in significant growth in the drug delivery market over the last few years. According to GBI Research, the overall drug delivery market is forecasted to grow to to $199 billion in 2016 from $101 billion in 2009, at a CAGR of 10.3%.

Central Nervous System (CNS) agents, hormone-related agents and gastrointestinal agents are among the key therapeutic areas witnessing the use of innovative drug delivery methods, and this trend is expected to grow in the coming years.

Oral Drug Delivery System is the Largest Segment of the Drug Delivery Market and is Expected to See Considerable Growth Especially for Controlled Release Drug Forms and Oral Forms of Injectible Only Drugs

The oral drug delivery market remains the largest segment of the overall drug delivery market, with more than 52% of the market share. It is presently valued at $49 billion and is expected to reach $92 billion by 2016, at a CAGR of 11.3%. The growth in the oral drug delivery market shall be driven primarily by newer technologies enabling controlled release formulations of oral drugs and oral formulations of injectible only drugs.

Other innovative technologies like nanotechnology-enabled oral drugs and oral forms of prodrugs have also seen significant research and development over the past few years, both in academic circles as well as in the industry as a whole.

Innovative oral formulations like orally disintegrating tablets, fast dissolving tablets and mini-tablets have been introduced into the market, which ensure better patient compliance, reduce dosage frequencies and enable customizable drug loading.

- Chiasma(Israel) Ltd
- Emisphere Technologies Inc
- Merrion Pharmaceuticals Plc
- Oramed Pharmaceuticals
- Samyang Corporation
- Unigene Laboratories Inc
- Bone Medical Limited
- Chimerix Inc
- Mucosis B.V
- Immupharma Plc
- Access Pharmaceuticals Inc
- ActogeniX NV
- Egalet
- Eurand N.V
- Supernus Pharmaceuticals,Inc

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos